Literature DB >> 4790621

Cephalexin concentrations in sputum during acute respiratory infections.

G M Halprin, S M McMahon.   

Abstract

In 20 patients with acute pulmonary infections, sputum purulence, sputum volume, and concentration and excretion of cephalexin in the sputum significantly decreased concurrently during therapy. The concentration of cephalexin in the serum remained unchanged. Significant correlations were observed between drug concentrations in sputum and serum and between drug excretion in sputum and concentration in serum. These observations may be explained by decreased integrity of the "blood-bronchus barrier" during inflammation, with diffusion of serum into bronchial mucus, without the necessity of postulating active transport.

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4790621      PMCID: PMC444484          DOI: 10.1128/AAC.3.6.703

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  12 in total

1.  AMPICILLIN IN THE THERAPY OF CHRONIC BRONCHITIS.

Authors:  J R MAY
Journal:  Postgrad Med J       Date:  1964-12       Impact factor: 2.401

2.  TREATMENT OF CHRONIC BRONCHITIS WITH AMPICILLIN: SOME PHARMACOLOGICAL OBSERVATION.

Authors:  J R MAY; D M DELVES
Journal:  Lancet       Date:  1965-05-01       Impact factor: 79.321

3.  Ampicillin levels in sputum, serum, and saliva.

Authors:  S M Stewart; M Fisher; J E Young; W Lutz
Journal:  Thorax       Date:  1970-05       Impact factor: 9.139

4.  In vivo penetration of antibiotics into sputum in cystic fibrosis.

Authors:  B A Saggers; D Lawson
Journal:  Arch Dis Child       Date:  1968-08       Impact factor: 3.791

5.  Cephalexin: in vitro bacterial susceptibility, absorption in volunteers, and antibacterial activity of sera and urine.

Authors:  R L Perkins; H N Carlisle; S Saslaw
Journal:  Am J Med Sci       Date:  1968-08       Impact factor: 2.378

6.  Some principles in the chemotherapy of bacterial infections. II.

Authors:  J Crofton
Journal:  Br Med J       Date:  1969-04-26

Review 7.  Clinical significance of protein binding of the penicillins.

Authors:  C M Kunin
Journal:  Ann N Y Acad Sci       Date:  1967-09-27       Impact factor: 5.691

8.  A guide to use of antibiotics in patients with renal disease. A table of recommended doses and factors governing serum levels.

Authors:  C M Kunin
Journal:  Ann Intern Med       Date:  1967-07       Impact factor: 25.391

9.  In vitro antimicrobial activity and human pharmacology of cephaloglycin.

Authors:  J M Applestein; E B Crosby; W D Johnson; D Kaye
Journal:  Appl Microbiol       Date:  1968-07

10.  In vitro antimicrobial activity and human pharmacology of cephalexin, a new orally absorbed cephalosporin C antibiotic.

Authors:  T S Thornhill; M E Levison; W D Johnson; D Kaye
Journal:  Appl Microbiol       Date:  1969-03
View more
  7 in total

Review 1.  Pulmonary disposition of antimicrobial agents: methodological considerations.

Authors:  D R Baldwin; D Honeybourne; R Wise
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

2.  Cefuroxime: pharmacokinetic study in bronchial secretions.

Authors:  E Bergogne-Berezin; P Even; G Berthelot; J Pierre
Journal:  Proc R Soc Med       Date:  1977

3.  Penetration of antibiotics into the respiratory tract.

Authors:  J Symonds
Journal:  Br Med J (Clin Res Ed)       Date:  1987-05-09

4.  Effect of protein concentration and binding on antibiotic assays.

Authors:  L R Peterson; E A Schierl; W H Hall
Journal:  Antimicrob Agents Chemother       Date:  1975-05       Impact factor: 5.191

5.  Anti-Pseudomonas activity in bronchial secretions of patients receiving amikacin or tobramycin as a continuous infusion.

Authors:  G Mombelli; L Coppens; J P Thys; J Klastersky
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

6.  Bronchial secretion levels of amikacin.

Authors:  W L Dull; M R Alexander; J E Kasik
Journal:  Antimicrob Agents Chemother       Date:  1979-12       Impact factor: 5.191

7.  In vitro and in vivo morphological response of Klebsiella pneumoniae to cefotiam and cefazolin.

Authors:  M Nakao; T Nishi; K Tsuchiya
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.